◆ AI Clinical Summary
Plain-language summary for patients
| NCT ID | NCT05081141 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Condition | HHV8 |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-09-15 |
| Primary Completion | 2024-12-31 |
Trial Parameters
Condition HHV8
Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study Type OBSERVATIONAL
Phase N/A
Enrollment 250
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-09-15
Completion 2024-12-31
All Conditions
Interventions
Diagnostic test for HHV8 exposure
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Solid organ transplant candidates will undergo serological screening for HHV8 at time of listing and transplantation. In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive recipient (R+), blood levels of HHV8 DNA will be monitored together with specific IGRA for HHV8.
Eligibility Criteria
SOT DONORS: Inclusion Criteria: * all donors used for transplantation purposes (kidney, liver, lung), including living donors in case of kidney transplantation Exclusion Criteria: * None SOT CANDIDATES RECIPIENTS: Inclusion Criteria: * All patients listed for solid organ transplantation (lung, liver and kidney) Exclusion Criteria: * None
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology